EPO‐GBR‐7.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 300, head and neck cancer (stage I‐IV); concomitant treatment: radiotherapy
Interventions	drug = Epoetin alpha dose = if Hb < 12.5 10000 IU sc TIW; if Hb > 12.5 4000 IU sc TIW hb‐target = 12.5‐15 g/dL planned ESA duration = during radiotherapy
Outcomes	Primary: local disease free survival; secondary: overall survival, QoL, safety
Notes	study number = 81645
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	central randomization schedule stratified by the study site was generated by the sponsor
Allocation concealment?	Unclear risk	no description